CA-COGNIGY
22.10.2020 11:02:10 CEST | Business Wire | Press release
Cognigy , a global leader in Conversational AI, today announced the release of Cognigy Voice Gateway (VG), an artificial intelligence voice solution, which deploys virtual agents (naturally-conversing voice bots) for automated inbound and outbound voice calls, whether via phone, web or mobile. Cognigy VG is designed to empower enterprises to automate high volume customer support requests and deliver high-quality, personalized experiences at scale on any channel and in any language.
In 2020, customer service teams in every industry have faced unprecedented issues that have led to staff cuts, workload distribution problems and more. Call centers have struggled with low satisfaction rates for years, due to long IVR menus, extended wait times, poor NLUs to solve customer problems, narrow channel options, and an overall lag in technological advancement.
Cognigy VG is a comprehensive solution that addresses these gaps. An enterprise-ready, AI-based Conversational IVR solution, it can deploy virtual voice agents, co-exist with existing technology, and enhance the work of human agents. With its advanced multi-tasking capabilities, Cognigy VG can handle thousands of parallel AI-phone calls with live audio streams in near-real-time. To ensure 24x7 operation along with integrity, redundant configurations with underlying voice gateway instances are available.
“Voice-based AI is the future of Customer Service and CX,” said Philipp Heltewig, CEO and co-founder of Cognigy. “Customer service teams have been overwhelmed throughout the pandemic, and we are leading the automation of conversations to make life easier for everyone. Cognigy Voice Gateway is now helping our global customers respond to pressures by scaling to demand, reducing call resolution times, and overcoming other major challenges, which is driving up satisfaction on many fronts.”
Highlights of Cognigy Voice Gateway:
- Intelligent conversational skills: Understands, interprets and analyzes voice calls to appropriately respond in human-like speech.
- Advanced technology: Employs next-generation AI technologies, including Machine Learning (ML), Natural Language Processing (NLP), Natural Language Generation, Sentiment Analysis, and Speech Recognition to provide the best quality output.
- Multi-tasking: Handles thousands of calls simultaneously and makes routine problem-solving easier and quicker for callers.
- Assistance to live agents : Speeds up routine calls, smoothly transferring calls to a live agent when an interaction requires human intervention.
- Security: Enterprise-grade security, GDPR privacy, compliance resilience and availability.
Listen to a sample automated phone interaction and learn more about Cognigy Voice Gateway at https://www.cognigy.com/products/voice-gateway .
About Cognigy
Cognigy is a global leader in Conversational AI Automation. Its platform, Cognigy.AI, enables enterprises to automate customer and employee communications using intelligent voice- and chatbots. With precise, reliable intent recognition, highly flexible dialogs and seamless integration into backend systems, Cognigy.AI creates superior user experiences and helps companies reduce Support costs and increase efficiency. Cognigy.AI is available in SaaS and on-premise environments and supports conversations in any language and on any channel including web, phone, SMS and mobile apps. Cognigy’s worldwide client portfolio includes Daimler, Bosch, Lufthansa, Salzburg AG and many more.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201022005008/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom